Cogent Biosciences (COGT) News Today $4.77 -0.56 (-10.51%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$4.78 +0.02 (+0.31%) As of 04/4/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week Low - Here's WhyCogent Biosciences (NASDAQ:COGT) Hits New 52-Week Low - What's Next?April 2 at 10:56 AM | marketbeat.comBrokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.43April 2 at 1:21 AM | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 7.7% - Time to Sell?Cogent Biosciences (NASDAQ:COGT) Shares Down 7.7% - Should You Sell?April 1, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, four have issued a buy recMarch 31, 2025 | marketbeat.comWe're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn RateMarch 29, 2025 | finance.yahoo.comEntryPoint Capital LLC Acquires Shares of 52,346 Cogent Biosciences, Inc. (NASDAQ:COGT)EntryPoint Capital LLC bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 52,346 shares of the technology company's stock, valued at approximately $408,000. Other large investors havMarch 27, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.1% - Here's WhyCogent Biosciences (NASDAQ:COGT) Trading Down 5.1% - What's Next?March 26, 2025 | marketbeat.comCogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comCogent Biosciences (NASDAQ:COGT) Shares Down 2.3% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 2.3% - Should You Sell?March 15, 2025 | marketbeat.comScotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform RecommendationMarch 8, 2025 | msn.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.3% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 5.3% - Time to Sell?March 8, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Coverage Initiated at ScotiabankScotiabank started coverage on shares of Cogent Biosciences in a research note on Friday. They set a "sector outperform" rating and a $17.00 price target for the company.March 8, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Cogent Biosciences (COGT)March 7, 2025 | markets.businessinsider.comCogent Biosciences Announces Participation in the Leerink Healthcare ConferenceMarch 7, 2025 | globenewswire.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation andMarch 5, 2025 | marketbeat.comY Intercept Hong Kong Ltd Purchases 43,472 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Y Intercept Hong Kong Ltd grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 137.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 75,037 shares of the technology company's stock after purchasing an aMarch 2, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Up 7.8% - What's Next?Cogent Biosciences (NASDAQ:COGT) Shares Up 7.8% - Time to Buy?February 28, 2025 | marketbeat.comRobert W. Baird Lowers Cogent Biosciences (NASDAQ:COGT) Price Target to $8.00Robert W. Baird cut their price objective on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday.February 28, 2025 | marketbeat.comCogent Biosciences announces expanded results from OLE portion of SUMMIT trialFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences price target lowered to $8 from $10 at BairdFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsFebruary 27, 2025 | globenewswire.comWedbush Research Analysts Boost Earnings Estimates for COGTCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates thaFebruary 27, 2025 | marketbeat.comNeedham Keeps Their Hold Rating on Cogent Biosciences (COGT)February 26, 2025 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Hold" Rating for Cogent Biosciences (NASDAQ:COGT)Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a research note on Wednesday.February 26, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Earns "Neutral" Rating from WedbushWedbush reissued a "neutral" rating and issued a $11.00 price target on shares of Cogent Biosciences in a report on Tuesday.February 25, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Issues Earnings Results, Beats Expectations By $0.50 EPSCogent Biosciences (NASDAQ:COGT - Get Free Report) posted its quarterly earnings data on Tuesday. The technology company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.50.February 25, 2025 | marketbeat.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 25, 2025 | globenewswire.comCogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short InterestCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 10,130,000 shares, an increase of 8.3% from the January 15th total of 9,350,000 shares. Based on an average daily volume of 1,590,000 shares, the days-to-cover ratio is presently 6.4 days.February 19, 2025 | marketbeat.comCogent Biosciences (COGT) Projected to Post Earnings on MondayCogent Biosciences (NASDAQ:COGT) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 5.9% - What's Next?Cogent Biosciences (NASDAQ:COGT) Shares Down 5.9% - Should You Sell?February 11, 2025 | marketbeat.comCogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual MeetingFebruary 10, 2025 | globenewswire.comLeerink Partnrs Has Optimistic View of COGT FY2025 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs upped their FY2025 earnings estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts thFebruary 10, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by BrokeragesCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the coFebruary 8, 2025 | marketbeat.comResearch Analysts Offer Predictions for COGT Q1 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Cogent Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the technologyFebruary 7, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Sees Strong Trading Volume - Here's What HappenedCogent Biosciences (NASDAQ:COGT) Sees Unusually-High Trading Volume - Time to Buy?February 6, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Sees Significant Increase in Short InterestCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 7,980,000 shares, an increase of 9.3% from the December 31st total of 7,300,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is currently 5.6 days.February 2, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 5.3% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 5.3% - Here's WhyJanuary 31, 2025 | marketbeat.comCogent Biosciences to Participate in the Guggenheim Biotech ConferenceJanuary 30, 2025 | finance.yahoo.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 4.2% - What's Next?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 4.2% - Time to Sell?January 24, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Acquired by SG Americas Securities LLCSG Americas Securities LLC grew its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 2,865.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 964,712 shares of the technology company's stock after acquiring an additional 932,179 sharesJanuary 24, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Up 7.3% - Still a Buy?Cogent Biosciences (NASDAQ:COGT) Trading 7.3% Higher - Still a Buy?January 23, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 133,515 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Assenagon Asset Management S.A. trimmed its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 22.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 473,693 shares of the technology company's stock after selling 133,51January 22, 2025 | marketbeat.comShort Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 9.3%Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 7,980,000 shares, a growth of 9.3% from the December 15th total of 7,300,000 shares. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 5.6 days.January 18, 2025 | marketbeat.comThis Cogent Biosciences Insider Increased Their Holding By 2,085% Last YearJanuary 18, 2025 | finance.yahoo.comHennion & Walsh Asset Management Inc. Buys 103,293 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Hennion & Walsh Asset Management Inc. boosted its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 60.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 275,292 shares of tJanuary 18, 2025 | marketbeat.comCogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST DataJanuary 18, 2025 | seekingalpha.comCogent Biosciences up 10% at $8.14 after disclosing insider buyJanuary 16, 2025 | markets.businessinsider.comCogent and ModivCare gain after insider purchasesJanuary 15, 2025 | msn.comCogent Biosciences (NASDAQ:COGT) Shares Gap Up - Time to Buy?Cogent Biosciences (NASDAQ:COGT) Shares Gap Up - Here's WhyJanuary 15, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Price Target Lowered to $14.00 at HC WainwrightHC Wainwright dropped their price target on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday.January 14, 2025 | marketbeat.com Remove Ads Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼0.410.61▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼53▲COGT Articles Average Week Remove Ads Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viking Therapeutics News HUTCHMED News Amneal Pharmaceuticals News ImmunityBio News Xenon Pharmaceuticals News MoonLake Immunotherapeutics News Biohaven News Bausch Health Companies News Twist Bioscience News NewAmsterdam Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COGT Stock Free COGT Stock Alerts